Market Restraint
Currently, there is no approved EBV vaccine in the market. Various barriers in the development and gaining approval for EBV vaccines is expected to be a major factor negatively effecting the market growth. Some of the barriers in development of an EBV vaccine include:
Some of the barrier related in development of EBV vaccine includes: the difficulty of performing clinical trials, lack of knowledge of immune correlates for protection against EBV infection and disease, and limitations in animal models to study protection against EBV infection and disease.
Universities and organizations involved in development of monovaccine (Epstein - Barr virus) include Cancer Research UK, National Institutes of Health, Chinese University of Hong Kong, Genocea Biosciences, Inc., Dana-Farber Cancer Institute, German Cancer Research Institute, and University of Minnesota.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients